PTCH1 mutant small cell glioblastoma in a patient with Gorlin syndrome: A case report.

Gorlin syndrome or nevoid basal cell carcinoma syndrome is a rare genetic disease characterized by predisposition to congenital defects, basal cell carcinomas and medulloblastoma. The syndrome results from a heritable mutation in PATCHED1 ( PTCH1 ), causing constitutive activation of the Hedgehog pathway. The present study described a patient with Gorlin syndrome who presented early in life with characteristic basal cell carcinomas and later developed a small cell glioblastoma (GBM), World Health Organization grade IV, associated with a Patched 1 ( PTCH1 ) N97fs*43 mutation. Comprehensive genomic profiling of GBM tissues also revealed multiple co-occurring alterations including cyclin-dependent kinase 4 ( CDK4 ) amplification, receptor tyrosine-protein kinase 3 ( ERBB3 ) amplification, a fibroblast growth factor receptor 1 and transforming acidic coiled-coil containing protein 1 ( FGFR1-TACC1 ) fusion, zinc finger protein ( GLI1 ) amplification, E3 ubiquitin-protein ligase ( MDM2 ) amplification and spectrin α chain, erythrocytic 1 ( SPTA1 ) T1151fs*24 . After the biopsy, imaging revealed extensive leptomeningeal enhancement intracranially and around the cervical spinal cord due to leptomeningeal disease. The patient underwent craniospinal radiation followed by 6 months of adjuvant temozolomide (150 mg/m ² ) with good response. She was then treated with vismodegib for 11 months, first combined with temozolomide and then with bevacizumab, until disease progression was noted on MRI, with no significant toxicities associated with the combination therapy. She received additional therapies but ultimately succumbed to the disease four months later. The current study presents the first documentation in the literature of a primary (non-radiation induced) glioblastoma secondary to Gorlin syndrome. Based on this clinical experience, vismodegib should be considered in combination with standard-of-care therapies for patients with known Gorlin syndrome-associated glioblastomas and sonic hedgehog pathway mutations.
Competing Interests: Nicholas Britt and Shakti H. Ramkissoon declare employment at Foundation Medicine. The remaining co-authors have no conflicts of interest to declare.
(Copyright: © Dorsey et al.)